← Back to home

Anti-3-hydroxy-3-methylglutaryl-coa reductase (HMGCR) immune-mediated necrotizing myopathy

Clinical trials for Anti-3-hydroxy-3-methylglutaryl-coa reductase (HMGCR) immune-mediated necrotizing myopathy explained in plain language.

Never miss a new study

Get alerted when new Anti-3-hydroxy-3-methylglutaryl-coa reductase (HMGCR) immune-mediated necrotizing myopathy trials appear

Sign up with your email to follow new studies for Anti-3-hydroxy-3-methylglutaryl-coa reductase (HMGCR) immune-mediated necrotizing myopathy, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Can immune therapy help rare muscle disorder?

Disease control Recruiting now

This phase 2 trial tests whether intravenous immunoglobulin (IVIG) can help people with a rare autoimmune muscle disease called anti-HMGCR immune-mediated necrotizing myopathy. Twelve participants will receive either IVIG or a placebo every 4 weeks for 12 weeks, then all may rece…

Matched conditions: ANTI-3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IMMUNE-MEDIATED NECROTIZING MYOPATHY

Phase 2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control

Last updated Aug 07, 2026 00:00 UTC

Anti-3-hydroxy-3-methylglutaryl-coa reductase (HMGCR) immune-mediated necrotizing myopathy

Get alerted when new Anti-3-hydroxy-3-methylglutaryl-coa reductase (HMGCR) immune-mediated necrotizing myopathy trials appear

Can immune therapy help rare muscle disorder?